How to Choose an Eye Drops Manufacturer in India: A Buyer's Evaluation Framework

India has thousands of pharmaceutical manufacturers, and a significant number claim ophthalmic capability. For a pharma distributor building an eye care portfolio, a hospital purchase manager qualifying vendors, or an entrepreneur considering a PCD (propaganda-cum-distribution) franchise, the challenge is not finding a manufacturer — it is separating the genuinely compliant, quality-consistent ones from the long tail that will eventually fail a batch, an inspection or a tender audit.

Having watched this market for years, our advice is to evaluate any eye drops manufacturer against six pillars. None of them is negotiable, and none can be verified from a brochure alone.

Pillar 1: Regulatory Standing

Start with paperwork, because it eliminates most of the field quickly.

• Manufacturing licence. The company must hold a valid manufacturing licence from its State Drugs Control Authority covering the specific ophthalmic products it offers you. Ask for the licence and the product permissions list — and check that the products you want are actually on it.
• CDSCO approvals where applicable. For molecules still in their "new drug" window (first four years after Indian approval) and for fixed-dose combinations, evidence of DCGI/CDSCO approval is required.
• GMP certification. Ask for WHO-GMP certification and, more importantly, for evidence of compliance with the revised Schedule M (notified December 2023), which explicitly covers sterile ophthalmic preparations. Post-2023, this is the enforceable standard, and risk-based CDSCO inspections are actively testing it.

Red flag: a manufacturer that supplies a generic "GMP certificate" but cannot produce its manufacturing licence, product-wise permissions, or recent inspection outcomes.

Pillar 2: Sterile Manufacturing Capability

Eye drops are sterile products, and sterility is a manufacturing outcome, not a test result. Probe the actual capability:

• Cleanroom grades. What classification is maintained at the filling point (ideally Grade A with Grade B background for aseptic filling)?
• Contamination Control Strategy (CCS). Under the revised Schedule M, a documented CCS is mandatory. A manufacturer that cannot summarise its CCS does not have one.
• Media fills. Ask when the last aseptic process simulation was performed, at what scale, and what the results were. This is the single most revealing quality question you can ask.
• Water and HVAC systems. Purified Water/WFI generation and HEPA-filtered air handling are the invisible backbone of ophthalmic quality; ask about monitoring and maintenance.
• Packaging technology. Blow-fill-seal (BFS) capability for unit doses, tamper-evident closures and validated container-closure integrity are marks of a serious sterile operation.

Pillar 3: Quality Control Depth

A manufacturer's QC laboratory tells you more about its culture than its marketing deck:

• Is microbiology done in-house (sterility, preservative efficacy, bioburden, environmental monitoring), or entirely outsourced?
• Which pharmacopoeia do methods follow — Indian Pharmacopoeia (IP) 2022, and harmonised USP/BP methods where relevant?
• Is there a documented stability programme aligned to ICH Q1A, with real-time data supporting the labelled shelf life of each product?
• Are batch-wise Certificates of Analysis provided with every dispatch, without having to chase them?

Ask for a sample CoA for a recent batch of a product you intend to stock. A quality-driven company treats this as routine; a weak one treats it as an imposition.

Pillar 4: Product Range and Formulation Quality

The commercial logic of ophthalmology favours breadth with depth:

Equally important is formulation literacy: pH and osmolality adjusted for comfort, preservative systems chosen with ocular surface safety in mind, and preservative-free options where chronic use demands them. Ask why the manufacturer chose its preservative concentrations — the answer reveals whether formulation is a science or a copy-paste exercise there.

Depth within each segment matters as much as breadth across segments: a lubricant "range" that is one CMC SKU is not a range, and a glaucoma offering without a fixed combination abandons the fastest-growing part of the category.

Pillar 5: Supply Reliability and Commercial Terms

Quality without reliability is unusable. Evaluate:

• Fill rates and lead times over the last 12 months — ask for numbers, not adjectives.
• Batch traceability — can they trace every unit from raw material lot to your invoice?
• Recall system — is there a validated, tested recall procedure? (Revised Schedule M requires documented recall arrangements.)
• Shelf life at delivery — reputable suppliers guarantee a minimum residual shelf life (commonly 60–75% of labelled life) on dispatch.
• Cold chain where relevant — some ophthalmics need controlled storage; verify the logistics.
• Credit terms, expiry-returns policy and price protection — get these in writing before the first order.

Pillar 6: Partnership Support

For distributors and franchise partners, the manufacturer's commercial support often determines success more than the price list:

• Monopoly or semi-exclusive territory terms (for PCD/franchise models)
• Visual aids, product literature, sample policy and CME/awareness support for ophthalmologists
• Tender support: documentation packs for institutional bids (licences, GMP, stability summaries, market-standing certificates)
• Responsive pharmacovigilance and complaint handling — a real adverse-event channel, not an email black hole

Three Engagement Models — Know Which One You're Buying

"Manufacturer" covers three distinct business arrangements, and confusing them causes most partnership failures:

1. PCD / franchise model. The manufacturer owns the brands; you take territory rights and market them. Evaluate brand strength, promotional support and exclusivity enforcement above all. Ask: how many franchisees already operate in adjacent territories, and how are boundary disputes handled?
2. Third-party / contract manufacturing. You own the brand; the factory makes it under a loan-licence or its own licence with your label. Here the quality pillars matter most — the product's regulatory and quality identity IS the factory. Insist on audit rights, a quality agreement defining responsibilities (deviations, complaints, recalls, stability), and visibility into batch records.
3. Institutional supply. You (or the manufacturer) bid for tenders and rate contracts. Evaluate documentation completeness, L1-costing discipline and the supplier's NSQ (Not of Standard Quality) history — one failed government lab test can poison tender eligibility for years.

Many Indian ophthalmic companies, including focused players, operate across all three — but your evaluation checklist should be tuned to the model you are actually signing.

Pitfalls That Cost Buyers Money

• Choosing on price list alone. A 5% cheaper drop that fails a tender audit or arrives with 8 months of shelf life is the most expensive option on the table.
• Ignoring minimum residual shelf life. Stock that expires in your godown is a direct margin leak; negotiate delivery-life guarantees and expiry-returns upfront.
• No verification visit. A one-day plant visit — cleanroom discipline, QC lab activity, documentation culture — reveals more than any certificate. A manufacturer that discourages visits is telling you something.
• Undocumented exclusivity. "You're our only partner in the district" means nothing unless it is written, territory-defined and breach-penalised.
• Skipping the complaint channel test. Send a technical query before signing. Response time and quality of answer is the best available preview of the relationship.

The First 90 Days: Proving the Partnership

Even a well-scored manufacturer should earn your full commitment in stages. A sensible onboarding path:

1. Order narrow, verify fast. Start with 3–5 fast-moving SKUs rather than the full catalogue. Measure fill rate, dispatch speed, residual shelf life and CoA completeness on the first three orders.
2. Test the complaint channel. Raise one technical query and one simulated batch complaint. Response quality here predicts the next three years.
3. Check chemist and prescriber feedback. Sample acceptance, packaging feel and bottle/nozzle usability reach you quickly from the field — and they predict repeat prescribing better than any spec sheet.
4. Then scale. Extend to chronic lines and institutional documentation packs only after the basics are proven.

This staged approach costs a few weeks and routinely saves distributors from catalogue-wide commitments to suppliers who pass the audit but fail the operating rhythm.

A Practical Scoring Approach

We recommend weighting the six pillars explicitly: Regulatory (25%), Sterile capability (20%), QC depth (20%), Range/formulation (15%), Reliability (10%), Support (10%). Score each candidate 1–5 per pillar and disqualify anyone scoring below 3 on the first two. It converts a fuzzy "vendor feel" decision into a defensible procurement record — exactly what a hospital audit or a tender committee wants to see. Revisit the scores annually: leadership changes, ownership transfers and capacity expansions all alter a manufacturer's quality trajectory, and yesterday's excellent partner can become tomorrow's supply risk without the paperwork ever changing.

Frequently Asked Questions

What licences should an eye drops manufacturer in India hold?

At minimum: a valid manufacturing licence from the State Drugs Control Authority with product-wise permissions for the items offered; evidence of CDSCO/DCGI approval for newer molecules and fixed-dose combinations; and GMP compliance per the revised Schedule M (December 2023), typically evidenced by WHO-GMP certification and recent inspection records.

What is the single best question to ask a prospective manufacturer?

"Tell me about your last media fill — when, at what scale, and what did it show?" The media fill result is the most direct evidence that an aseptic line actually produces sterile product, and the willingness to discuss it signals transparency about the quality system as a whole.

Is third-party (contract) manufacturing reliable for eye drops?

It can be — provided the contract site itself meets the sterile-manufacturing pillars above. Many respected Indian ophthalmic brands are made on qualified third-party lines. What matters is not whose name is on the factory gate, but the licence, the CCS, the media fills, the QC depth and the batch documentation behind the product.

How important is product range when choosing a manufacturer?

Very. Ophthalmology distribution economics reward a full basket: peri-operative anti-infectives and combinations, chronic glaucoma lines, a lubricant ladder, anti-allergy and eye nutrition. A single-product supplier forces you to manage multiple vendors for what one good partner can provide.

What commercial terms should distributors lock in upfront?

Territory/exclusivity terms, price lists with revision mechanics, minimum order quantities, guaranteed residual shelf life at delivery, expiry and breakage returns policy, credit period, tender documentation support and a defined complaint/pharmacovigilance channel. Verbal assurances are worth nothing at the first dispute.

---

This article provides general industry guidance for B2B buyers and does not constitute legal, regulatory or commercial advice.

Evaluating ophthalmic manufacturing partners? Oculentis Medical provides complete documentation packs, quality samples and distributor support. Become a distributor or request samples to start your evaluation.